Changeflow GovPing Healthcare & Life Sciences NF-κB Inhibitors for Cancer, Inflammatory Diseases
Routine Rule Added Final

NF-κB Inhibitors for Cancer, Inflammatory Diseases

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO granted Patent US12606528B2 to the University of Pittsburgh covering compounds that inhibit NF-κB activity and their use in treating cancer, inflammatory conditions, and autoimmune diseases. The patent names Beibei Chen, Toren Finkel, and Yuan Liu as inventors and contains 33 claims. The patent application was filed on November 20, 2020.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Grants - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 190 changes logged to date.

What changed

The USPTO issued Patent US12606528B2 granting the University of Pittsburgh exclusive rights to NF-κB inhibitor compounds and methods of using them for therapeutic applications. The patent covers pharmaceutical compositions and methods for treating diseases associated with NF-κB activity, including cancer (A61P 35/00), inflammatory conditions (A61P 29/00), and autoimmune diseases (A61P 37/00).

For the assignee University of Pittsburgh, this grant provides enforceable patent rights for commercializing the disclosed compounds. Competitors developing NF-κB inhibitors for similar therapeutic uses should conduct freedom-to-operate analyses to assess potential infringement exposure.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods and materials for inhibiting NF-kB activity

Grant US12606528B2 Kind: B2 Apr 21, 2026

Assignee

UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventors

Beibei Chen, Toren Finkel, Yuan Liu

Abstract

This document provides compounds that are inhibitors of NF-κB activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, or autoimmune diseases.

CPC Classifications

A61K 31/421 A61K 31/426 A61K 31/4164 A61P 29/00 A61P 35/00 A61P 37/00

Filing Date

2020-11-20

Application No.

17778492

Claims

33

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606528B2

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Pharmaceutical IP
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!